PVR is a ligand of the TIGIT immune checkpoint receptor and is upregulated at the mRNA level in the mouse ccRCC model as well as at the protein level in human ccRCC, suggesting that blocking TIGIT activation could also be investigated for ccRCC therapy. Here, PVR is linked to nonpapillary renal cell carcinoma.